Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Intractable epilepsy in children poses significant treatment challenges.
• Existing antiepileptic drugs (AEDs) may not achieve adequate seizure control.
• Novel therapeutic strategies are crucial for managing refractory pediatric epilepsy.

Purpose of the Study:

• To evaluate the efficacy and safety of zonisamide (ZNS) as an add-on therapy for children with intractable epilepsy.
• To assess seizure reduction rates and identify adverse events associated with ZNS treatment.
• To determine the effectiveness of ZNS across different seizure types in pediatric populations.

Main Methods:

• A retrospective clinical study was conducted from 2003 to 2005 at two tertiary epilepsy centers.
• Data from 163 pediatric patients with intractable epilepsy (frequent seizures despite ≥2 AEDs) were analyzed.
• Efficacy was measured by seizure reduction rates, including seizure freedom, and adverse events were systematically recorded.

Main Results:

• 48.5% of patients achieved >50% seizure reduction, with 15.3% becoming seizure-free.
• Effective seizure reduction was observed in partial seizures (40.5%), generalized seizures (51.2%), and myoclonic seizures (55.6%).
• Adverse events occurred in 9.2% of patients (somnolence, fatigue, anorexia), were generally transient, and manageable; one case of pancreatitis led to discontinuation.

Conclusions:

• Zonisamide (ZNS) adjunctive therapy is an effective treatment for various types of intractable childhood epilepsy.
• The safety profile of ZNS is favorable, with manageable and transient adverse events.
• ZNS represents a valuable therapeutic option for pediatric patients with refractory epilepsy.